Ascendis Pharma A/S
ASND- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001612042
In the last 90 days, Ascendis Pharma A/S insiders filed 1 open-market purchase and 2 sales; 315 institutions reported holding it in 13F filings for Q2 2026, worth $17.8B in total; no superinvestor holds it.
- Currency
- EUR
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:42 PM ET
Amounts are in EUR, the currency Ascendis Pharma A/S reports in. Lines marked ≈ US$ convert key figures to US dollars.
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: EUR 228.0M (31.7% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Revenue | EUR 720.1M≈ US$814.2M | EUR 363.6M≈ US$393.5M | EUR 266.7M≈ US$288.5M | EUR 51.2M≈ US$53.9M | EUR 7.78M≈ US$9.20M |
| Cost of revenue | EUR 94.9M | EUR 44.3M | EUR 44.4M | EUR 12.1M | EUR 3.52M |
| Gross profit | EUR 625.2M | EUR 319.4M | EUR 222.3M | EUR 39.0M | EUR 4.25M |
| Research and development | EUR 303.6M | EUR 307.0M | EUR 413.5M | EUR 379.6M | EUR 295.9M |
| Selling, general and administrative | EUR 457.9M | EUR 291.1M | EUR 264.4M | EUR 221.2M | EUR 160.2M |
| Operating income | EUR -136.3M | EUR -278.8M | EUR -455.5M | EUR -561.8M | EUR -451.8M |
| Interest expense | EUR 206.7M | EUR 100.0M | EUR 44.1M | EUR 50.5M | EUR 3.91M |
| Income tax | EUR 15.4M | EUR 4.84M | EUR 7.30M | EUR 5.38M | EUR -367.0K |
| Net income | EUR -228.0M≈ US-$257.8M | EUR -378.1M≈ US-$409.1M | EUR -481.4M≈ US-$520.8M | EUR -583.2M≈ US-$614.4M | EUR -383.6M≈ US-$453.8M |
| EPS, basic | EUR -3.76 | EUR -6.53 | EUR -8.55 | – | – |
| EPS, diluted | EUR -3.76 | EUR -6.53 | EUR -8.55 | – | – |
| Weighted shares, basic | 60.6M | 57.9M | 56.3M | 56.1M | 54.8M |
| Margins and growth | |||||
| Gross margin | 86.8% | 87.8% | 83.4% | 76.3% | 54.7% |
| Operating margin | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% |
| Net margin | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% |
| Revenue growth, year over year | +98.0% | +36.3% | +421.2% | +557.9% | +11.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Cash and equivalents | EUR 616.0M | EUR 559.5M | EUR 392.2M | EUR 444.8M | EUR 446.3M |
| Accounts receivable | EUR 141.3M | EUR 166.3M | EUR 35.9M | EUR 11.9M | EUR 2.20M |
| Inventory | EUR 301.5M | EUR 295.6M | EUR 208.9M | EUR 130.7M | EUR 75.4M |
| Total current assets | EUR 1.11B | EUR 1.06B | EUR 702.7M | EUR 923.5M | EUR 805.9M |
| Property, plant and equipment | EUR 146.5M | EUR 98.7M | EUR 110.6M | EUR 129.1M | EUR 126.0M |
| Intangible assets | EUR 3.71M | EUR 4.03M | EUR 4.42M | EUR 4.83M | EUR 5.27M |
| Total assets | EUR 1.30B≈ US$1.53B | EUR 1.18B≈ US$1.22B | EUR 825.6M≈ US$913.3M | EUR 1.09B≈ US$1.17B | EUR 1.08B≈ US$1.23B |
| Accounts payable | EUR 90.7M | EUR 96.4M | EUR 94.6M | EUR 101.0M | EUR 59.4M |
| Short-term debt | EUR 429.4M | EUR 458.2M | EUR 11.2M | EUR 25.4M | – |
| Total current liabilities | EUR 1.07B | EUR 907.9M | EUR 197.3M | EUR 171.3M | EUR 100.4M |
| Long-term debt | EUR 385.3M | EUR 365.1M | EUR 534.2M | EUR 483.0M | – |
| Total liabilities | EUR 1.47B | EUR 1.29B | EUR 971.3M | EUR 826.4M | EUR 201.3M |
| Shareholders' equity | EUR -162.8M | EUR -105.7M | EUR -145.7M | EUR 263.3M | EUR 883.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Operating cash flow | EUR 53.9M≈ US$60.9M | EUR -306.2M≈ US-$331.3M | EUR -467.4M≈ US-$505.5M | EUR -495.7M≈ US-$522.2M | EUR -417.6M≈ US-$494.1M |
| Capital expenditures | – | – | EUR 2.44M | EUR 14.5M | EUR 23.7M |
| Free cash flow | – | – | EUR -469.8M≈ US-$508.2M | EUR -510.2M≈ US-$537.4M | EUR -441.4M≈ US-$522.1M |
| Stock-based compensation | EUR 116.2M | EUR 95.5M | EUR 66.7M | EUR 64.2M | EUR 66.8M |
| Share buybacks | EUR 17.4M | EUR 0 | EUR 0 | EUR 105.3M | EUR 21.6M |
| Investing cash flow | EUR -8.48M | EUR 6.88M | EUR 286.5M | EUR 61.7M | EUR -110.6M |
| Financing cash flow | EUR 36.3M | EUR 443.9M | EUR 134.3M | EUR 396.8M | EUR 351.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 16.1% | 26.3% | 25.0% | 125.4% | 859.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Dec 31, 2025 | 62.0M | +2.1% | SEC |
| Dec 31, 2024 | 60.7M | +5.2% | SEC |
| Dec 31, 2023 | 57.7M | +1.0% | SEC |
| Dec 31, 2022 | 57.2M | +0.4% | SEC |
| Dec 31, 2021 | 56.9M | +5.9% | SEC |
| Dec 31, 2020 | 53.8M | +12.0% | SEC |
| Dec 31, 2019 | 48.0M | +13.9% | SEC |
| Dec 31, 2018 | 42.1M | +13.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- ≈ US$ figures convert EUR at FRED H.10 exchange rates (Federal Reserve): the average rate over the period for income and cash flow, and the rate on the period-end date, or the last business day before it, for the balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.